Busuioc Mihaela, Gusbeth-Tatomir P, Covic A
Clinica a IV-a Medicală-Nefrologie, Spitalul Clinic "Dr. C.I. Parhon" Iaşi.
Rev Med Chir Soc Med Nat Iasi. 2009 Oct-Dec;113(4):984-90.
Acute kidney injury is a common complication in hospitalized patients, and its incidence has risen significantly in the past 15 yr. Despite significant technical advances in therapeutics, the mortality and morbidity rates associated with acute kidney injury remain dismally high and have not appreciably improved during the past four decades. An ideal biomarker for acute kidney injury would help clinicians and scientists diagnose the most common form of acute kidney injury, acute tubular necrosis, early and accurately and may aid to risk stratify patients with acute kidney injury by predicting the need for renal replacement therapy, the duration of acute kidney injury, the length of stay, and mortality. The major types of urinary biomarkers fall into three classes: 1) inflammatory; 2) renal tubular proteins that are excreted into the urine after injury; 3) surrogate markers of tubular injury. There has been increasing interest in the identification and validation of novel biomarkers of acute kidney injury that permit earlier and more accurate diagnosis.
急性肾损伤是住院患者常见的并发症，在过去15年中其发病率显著上升。尽管治疗技术取得了重大进展，但与急性肾损伤相关的死亡率和发病率仍然居高不下，在过去四十年中并未明显改善。理想的急性肾损伤生物标志物将有助于临床医生和科学家早期准确诊断最常见的急性肾损伤形式——急性肾小管坏死，并可能通过预测肾替代治疗的需求、急性肾损伤的持续时间、住院时间和死亡率，帮助对急性肾损伤患者进行风险分层。主要的尿生物标志物类型分为三类：1）炎症性；2）损伤后排泄到尿液中的肾小管蛋白；3）肾小管损伤的替代标志物。人们对鉴定和验证能够实现更早、更准确诊断的新型急性肾损伤生物标志物的兴趣与日俱增。
